SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Immunology and inflammation
Novartis Unites With Relation in $1.7B Inflammatory Skin Disease Pact
At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases and guide clinical development programs.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, coins, and arrow up on the red and paper background. Concept of business and financial growth.
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
A mid-stage study for ABI-5366 will begin mid next year, while Assembly continues to assess the Phase II potential of ABI-1179.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Traffic light in green color, with the dusk sky in the background.
Manufacturing
FDA’s Manufacturing Designation Could Derisk Mid-Development Manufacturing Changes
The status could support staged transitions to new manufacturing processes, potentially mitigating some risks of high-stakes switches.
December 9, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Microscope icon. Molecule and communication background. Connected lines with dots.
China
With Chinese Assets in Hand, Pharma Is Wondering What Else Can Be Learned
What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s Fangning Zhang says.
December 9, 2025
 · 
3 min read
 · 
Annalee Armstrong
Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic
Insights
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems now fueling early pilots in medical writing, patient engagement and regulatory workflows across the industry.
December 8, 2025
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Top view of a white boat with a train sailing to the blue sea
Weight loss
Wave Soars on Early Results for Obesity Treatment That Could ‘Disrupt’ the Landscape
Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, with 4% fat reduction after three months, beating Novo Nordisk’s semaglutide at a similar time point.
December 8, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Orlando, Florida
Cancer
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare diseases.
December 8, 2025
 · 
5 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Duchenne muscular dystrophy
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
December 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS